Supernus Announces Second Quarter 2024 Financial Results
Supernus Pharmaceuticals (Nasdaq: SUPN) reported strong financial results for Q2 2024. Total revenues increased 24% to $168.3 million, driven by significant growth in Qelbree and GOCOVRI sales. Qelbree net sales surged 92% to $59.4 million, while GOCOVRI net sales grew 10% to $31.7 million. The company achieved operating income of $22.6 million and adjusted operating earnings of $45.5 million. Supernus raised its full-year 2024 guidance for total revenues and operating earnings. The company also made progress in its product pipeline, including SPN-820 for depression and SPN-817 for epilepsy.
Supernus Pharmaceuticals (Nasdaq: SUPN) ha riportato risultati finanziari solidi per il secondo trimestre del 2024. I ricavi totali sono aumentati del 24% raggiungendo i 168,3 milioni di dollari, grazie a una crescita significativa delle vendite di Qelbree e GOCOVRI. Le vendite nette di Qelbree sono aumentate del 92% a 59,4 milioni di dollari, mentre le vendite nette di GOCOVRI sono cresciute del 10% a 31,7 milioni di dollari. L'azienda ha ottenuto un reddito operativo di 22,6 milioni di dollari e utili operativi rettificati di 45,5 milioni di dollari. Supernus ha elevato le previsioni per l'intero anno 2024 riguardo ai ricavi totali e agli utili operativi. Inoltre, l'azienda ha fatto progressi nel suo portafoglio prodotti, inclusi SPN-820 per la depressione e SPN-817 per l'epilessia.
Supernus Pharmaceuticals (Nasdaq: SUPN) reportó resultados financieros sólidos para el segundo trimestre de 2024. Los ingresos totales aumentaron un 24% a 168.3 millones de dólares, impulsados por un crecimiento significativo en las ventas de Qelbree y GOCOVRI. Las ventas netas de Qelbree se dispararon un 92% a 59.4 millones de dólares, mientras que las ventas netas de GOCOVRI crecieron un 10% a 31.7 millones de dólares. La compañía alcanzó un ingreso operativo de 22.6 millones de dólares y ganancias operativas ajustadas de 45.5 millones de dólares. Supernus elevó su guía para el total de ingresos y ganancias operativas para todo el año 2024. La compañía también avanzó en su cartera de productos, incluidos SPN-820 para la depresión y SPN-817 para la epilepsia.
슈퍼너스 제약(Supernus Pharmaceuticals, Nasdaq: SUPN)은 2024년 2분기 강력한 재무 실적을 발표했습니다. 총 수익은 24% 증가하여 1억 6,830만 달러에 달하였으며, 이는 Qelbree와 GOCOVRI 판매의 상당한 증가에 의해 주도되었습니다. Qelbree의 순매출은 92% 증가하여 5,940만 달러에 이르렀고, GOCOVRI의 순매출은 10% 증가하여 3,170만 달러에 도달했습니다. 이 회사는 영업수익 2,260만 달러와 조정된 영업 이익 4,550만 달러를 달성했습니다. 슈퍼너스는 전체 2024년 수익 및 영업 이익에 대한 가이던스를 상향 조정했습니다. 또한, SPN-820(우울증) 및 SPN-817(간질)을 포함한 제품 파이프라인에서도 진전을 이루었습니다.
Supernus Pharmaceuticals (Nasdaq: SUPN) a annoncé de solides résultats financiers pour le deuxième trimestre de 2024. Les revenus totaux ont augmenté de 24% pour atteindre 168,3 millions de dollars, grâce à une croissance significative des ventes de Qelbree et GOCOVRI. Les ventes nettes de Qelbree ont explosé de 92% pour atteindre 59,4 millions de dollars, tandis que les ventes nettes de GOCOVRI ont augmenté de 10% pour s'établir à 31,7 millions de dollars. L'entreprise a réalisé un revenu opérationnel de 22,6 millions de dollars et un bénéfice opérationnel ajusté de 45,5 millions de dollars. Supernus a relevé ses prévisions annuelles 2024 concernant les revenus totaux et les bénéfices d'exploitation. L'entreprise a également progressé dans son portefeuille de produits, incluant SPN-820 pour la dépression et SPN-817 pour l'épilepsie.
Supernus Pharmaceuticals (Nasdaq: SUPN) hat starke Finanzergebnisse für das zweite Quartal 2024 gemeldet. Die Gesamterlöse stiegen um 24% auf 168,3 Millionen US-Dollar, was auf ein signifikantes Wachstum der Verkaufszahlen von Qelbree und GOCOVRI zurückzuführen ist. Die Nettoumsätze von Qelbree stiegen um 92% auf 59,4 Millionen US-Dollar, während die Nettoumsätze von GOCOVRI um 10% auf 31,7 Millionen US-Dollar wuchsen. Das Unternehmen erzielte ein Betriebsergebnis von 22,6 Millionen US-Dollar und beigeordnete Betriebserträge von 45,5 Millionen US-Dollar. Supernus hob die Prognose für die Gesamterlöse und Betriebserträge für das gesamte Jahr 2024 an. Zudem machte das Unternehmen Fortschritte in seiner Produktpipeline, einschließlich SPN-820 gegen Depressionen und SPN-817 gegen Epilepsie.
- Total revenues increased 24% to $168.3 million in Q2 2024
- Qelbree net sales grew 92% to $59.4 million in Q2 2024
- GOCOVRI net sales increased 10% to $31.7 million in Q2 2024
- Operating income of $22.6 million in Q2 2024, compared to a loss in Q2 2023
- Adjusted operating earnings rose to $45.5 million in Q2 2024 from $10.0 million in Q2 2023
- Raised full-year 2024 guidance for total revenues and operating earnings
- Cash, cash equivalents, and marketable securities increased to $347.2 million as of June 30, 2024
- Trokendi XR net sales declined 12% to $17.1 million in Q2 2024 due to generic erosion
- Royalty, licensing and other revenues decreased 20% to $5.8 million in Q2 2024
Insights
Supernus Pharmaceuticals' Q2 2024 results show strong growth in key areas. Qelbree's net sales surged
The company's adjusted operating earnings (non-GAAP) saw a significant jump to
Supernus has raised its full-year 2024 guidance, now expecting total revenues between
Supernus' pipeline progress is noteworthy. The SPN-820 study for treatment-resistant depression has enrolled nearly
The interim analysis of SPN-817 for treatment-resistant seizures shows promise, with full results expected in H2 2024. The planned Phase IIb study for focal seizures indicates the company's commitment to expanding its epilepsy portfolio.
The initiation of a Phase I study for SPN-443, a novel stimulant for ADHD/CNS, demonstrates Supernus' continued focus on CNS disorders. These pipeline advancements, particularly in treatment-resistant conditions, could significantly enhance the company's market position in the CNS space if successful.
Qelbree's performance is particularly impressive, with IQVIA prescriptions up
The company's strategy of focusing on CNS disorders appears to be paying off, with growth in key products offsetting the decline in Trokendi XR due to generic competition. The diversification of revenue sources and pipeline development in areas like depression and epilepsy could help mitigate risks associated with patent expirations.
With a strong cash position of
- Net sales of Qelbree® increased
92% in the second quarter of 2024, compared to the same period in 2023.
$59.4 million and$104.5 million of net sales in the second quarter and first six months of 2024, respectively.
- Net sales of GOCOVRI® increased
10% in the second quarter of 2024, compared to the same period in 2023.
$31.7 million and$58.3 million of net sales in the second quarter and first six months of 2024, respectively.
- Total revenues were
$168.3 million in the second quarter of 2024, an increase of24% compared to the same period in 2023.
- Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased
32% in the second quarter of 2024, compared to the same period in 2023.
- Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased
- Operating income of
$22.6 million and$19.4 million in the second quarter and first six months of 2024. - Adjusted operating earnings (non-GAAP)(1) was
$45.5 million and$67.7 million in the second quarter and first six months of 2024, respectively, compared to$10.0 million and$40.5 million in the same periods in 2023. - Raising full year 2024 guidance for total revenues and operating earnings (GAAP and Non-GAAP).
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter of 2024 and associated Company developments.
Business Highlights
- Total IQVIA prescriptions for Qelbree were 184,342 in the second quarter 2024, an increase of
26% compared to the same period in the prior year. - In August 2024, the Company resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations ("off" episodes) in Parkinson’s disease.
“In the second quarter of 2024, we delivered strong net sales growth from our key growth drivers, Qelbree and GOCOVRI, as well as strong growth in adjusted operating earnings. We also advanced our product pipeline, announcing interim results from our open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures, and continued to progress SPN-820 through two Phase 2 studies in patients with depression," said Jack Khattar, President and CEO of Supernus. “Continued growth from Qelbree and GOCOVRI, together with pipeline progress, gives us confidence in delivering on our increased guidance and our operational objectives for 2024."
Product Pipeline Update
SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression
- Nearly three-quarters of the planned patients have been enrolled in the ongoing Phase IIb multi-center randomized double-blind placebo-controlled parallel design study of SPN-820 in adults with treatment-resistant depression. The study will examine the efficacy and safety of SPN-820 over a course of five weeks of treatment in approximately 268 patients in up to 50 clinical sites. The primary outcome measure is the change from baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. Topline data from the Phase IIb trial are expected in the first half of 2025.
- Enrollment is ongoing in the Phase II open-label study in patients with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, as well as onset of efficacy. Topline results from the study are expected by the end of 2024.
SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy
- In May 2024, the Company announced data from the planned interim analysis of its exploratory open-label Phase IIa clinical study of SPN-817 for treatment-resistant seizures. The interim analysis was based on 41 enrolled subjects, of which 19 completed the maintenance period. The Company continues to expect topline results for the full study in the second half of 2024.
- A Phase IIb randomized, double-blind, placebo-controlled study in patients with treatment resistant focal seizures is expected to start by the end of 2024.
SPN-443 – Novel stimulant for ADHD/CNS
- The Company plans to initiate a Phase I single dose study in healthy adults in 2024 following submission of an Investigational New Drug application. The primary objective of the study is to assess safety and tolerability.
Financial Highlights
This section includes information on non-GAAP financial measures. See “Non-GAAP Financial Information” section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.
Revenues
The following table provides information regarding total revenues (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2024 | 2023 | Change % | 2024 | 2023 | Change % | ||||||||||||||||||
| Net product sales | |||||||||||||||||||||||
| Qelbree | $ | 59.4 | $ | 31.0 | 92 | % | $ | 104.5 | $ | 56.8 | 84 | % | |||||||||||
| GOCOVRI | 31.7 | 28.8 | 10 | % | 58.3 | 54.8 | 6 | % | |||||||||||||||
| Oxtellar XR | 29.5 | 23.8 | 24 | % | 56.5 | 52.7 | 7 | % | |||||||||||||||
| APOKYN | 17.3 | 17.6 | (2 | )% | 33.9 | 34.8 | (2 | )% | |||||||||||||||
| Trokendi XR | 17.1 | 19.3 | (12 | )% | 33.1 | 54.1 | (39 | )% | |||||||||||||||
| Other(2) | 7.5 | 7.8 | (4 | )% | 14.7 | 15.7 | (6 | )% | |||||||||||||||
| Total net product sales | 162.5 | 128.3 | 27 | % | 301.0 | 268.9 | 12 | % | |||||||||||||||
| Royalty, licensing and other revenues(3) | 5.8 | 7.2 | (20 | )% | 11.0 | 20.4 | (46 | )% | |||||||||||||||
| Total revenues | $ | 168.3 | $ | 135.5 | 24 | % | $ | 312.0 | $ | 289.3 | 8 | % | |||||||||||
| Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) | $ | 121.7 | $ | 92.4 | 32 | % | $ | 222.4 | $ | 182.5 | 22 | % | |||||||||||
- Total revenues were
$168.3 million and$312.0 million for the three and six months ended June 30, 2024, compared to$135.5 million and$289.3 million in the same period in 2023.- Total net product sales were
$162.5 million and$301.0 million for the three and six months ended June 30, 2024, compared to$128.3 million and$268.9 million in the same period in 2023, respectively. The increase in both periods was primarily due to the increase in net sales of Qelbree, GOCOVRI and Oxtellar XR, partially offset by the decline in net product sales of Trokendi XR due to generic erosion. - Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP) increased
32% and22% for the three and six months ended June 30, 2024, compared to the same period in 2023.
- Total net product sales were
Other Financial Highlights
- Operating earnings was
$22.6 million and$19.4 million for the three and six months ended June 30, 2024, compared to operating loss of$(17.6) million and$(12.4) million for the same periods in 2023, respectively. The positive increase in both periods was primarily due to an increase in total net product sales. - Adjusted operating earnings (non-GAAP) were
$45.5 million and$67.7 million for the three and six months ended June 30, 2024, compared to$10.0 million and$40.5 million for the same periods in 2023, respectively. - Net earnings (loss) and diluted earnings (loss) per share were
$19.9 million and$0.36 for the three months and$20.0 million and$0.36 for the six months ended June 30, 2024, respectively, compared to$(0.8) million and$(0.02) for the three months and$16.1 million and$0.29 for the six months ended June 30, 2023, respectively. - At June 30, 2024, cash, cash equivalents, and current and long-term marketable securities were approximately
$347.2 million compared to$271.5 million as of December 31, 2023. This increase was primarily due to cash generated from operations.
Full Year 2024 Financial Guidance
For the full year 2024, the Company is increasing prior financial guidance for total revenues, GAAP operating earnings (loss) and non-GAAP operating earnings, and maintaining guidance for combined R&D and SG&A expenses as set forth below (dollars in millions).
| Current Guidance (as of August 6, 2024) | Previous Guidance (as of May 8, 2024) | ||
| Total revenues (includes approximately | |||
| Combined R&D and SG&A expenses | |||
| Operating earnings (loss) | |||
| Adjusted operating earnings (non-GAAP)(1) | |||
Non-GAAP Financial Information
This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. In addition to non-GAAP adjusted operating earnings, we also present total revenues excluding net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company’s revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.
There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company’s 2024 financial guidance is also being provided on both a GAAP and a non-GAAP basis.
| End Notes |
(1) See the section titled “Non-GAAP Financial Information” for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.
(2) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®.
(3) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, other licensed products and intellectual property.
(4) Includes net product sales and royalty, licensing, and other revenue.
(5) Reflects continued generic erosion of Trokendi XR and generic erosion of Oxtellar XR beginning in September 2024.
Conference Call Details
Supernus will host a conference call and webcast today, August 6, 2024, at 4:30 p.m. Eastern Time to discuss these results. A live webcast will be available in the Events & Presentations section of the Company’s Investor Relations website www.supernus.com/Investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
| Supernus Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except share data) | |||||||
| June 30, | December 31, | ||||||
| 2024 | 2023 | ||||||
| (unaudited) | |||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 52,089 | $ | 75,054 | |||
| Marketable securities | 295,098 | 179,820 | |||||
| Accounts receivable, net | 152,494 | 144,155 | |||||
| Inventories, net | 68,155 | 77,408 | |||||
| Prepaid expenses and other current assets | 23,166 | 16,676 | |||||
| Total current assets | 591,002 | 493,113 | |||||
| Long-term marketable securities | — | 16,617 | |||||
| Property and equipment, net | 12,274 | 13,530 | |||||
| Intangible assets, net | 559,644 | 599,889 | |||||
| Goodwill | 117,019 | 117,019 | |||||
| Other assets | 35,890 | 37,505 | |||||
| Total assets | $ | 1,315,829 | $ | 1,277,673 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | $ | 82,611 | $ | 79,569 | |||
| Accrued product returns and rebates | 175,119 | 154,274 | |||||
| Contingent consideration, current portion | 47,303 | 52,070 | |||||
| Other current liabilities | 3,623 | 4,283 | |||||
| Total current liabilities | 308,656 | 290,196 | |||||
| Contingent consideration, long-term | 697 | 1,380 | |||||
| Operating lease liabilities, long-term | 30,294 | 33,196 | |||||
| Deferred income tax liabilities, net | 11,440 | 24,963 | |||||
| Other liabilities | 7,288 | 6,422 | |||||
| Total liabilities | 358,375 | 356,157 | |||||
| Stockholders’ equity | |||||||
| Common stock, | 55 | 55 | |||||
| Additional paid-in capital | 455,170 | 439,493 | |||||
| Accumulated other comprehensive loss, net of tax | (372 | ) | (593 | ) | |||
| Retained earnings | 502,601 | 482,561 | |||||
| Total stockholders’ equity | 957,454 | 921,516 | |||||
| Total liabilities and stockholders’ equity | $ | 1,315,829 | $ | 1,277,673 | |||
| Supernus Pharmaceuticals, Inc. Condensed Consolidated Statements of Earnings (Loss) (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||
| Revenues | |||||||||||||||
| Net product sales | $ | 162,538 | $ | 128,336 | $ | 300,999 | $ | 268,911 | |||||||
| Royalty, licensing and other revenues | 5,787 | 7,227 | 10,970 | 20,416 | |||||||||||
| Total revenues | 168,325 | 135,563 | 311,969 | 289,327 | |||||||||||
| Costs and expenses | |||||||||||||||
| Cost of goods sold(a) | 17,916 | 21,091 | 34,225 | 44,551 | |||||||||||
| Research and development | 26,183 | 24,379 | 51,113 | 45,591 | |||||||||||
| Selling, general and administrative | 85,904 | 86,782 | 172,420 | 172,379 | |||||||||||
| Amortization of intangible assets | 20,108 | 20,108 | 40,245 | 40,074 | |||||||||||
| Contingent consideration expense (gain) | (4,355 | ) | 790 | (5,450 | ) | (857 | ) | ||||||||
| Total costs and expenses | 145,756 | 153,150 | 292,553 | 301,738 | |||||||||||
| Operating earnings (loss) | 22,569 | (17,587 | ) | 19,416 | (12,411 | ) | |||||||||
| Other income (expense) | |||||||||||||||
| Interest and other income, net | 3,733 | 1,370 | 7,129 | 6,716 | |||||||||||
| Interest expense | — | (910 | ) | — | (2,415 | ) | |||||||||
| Total other income (expense) | 3,733 | 460 | 7,129 | 4,301 | |||||||||||
| Earnings (loss) before income taxes | 26,302 | (17,127 | ) | 26,545 | (8,110 | ) | |||||||||
| Income tax expense (benefit) | 6,386 | (16,296 | ) | 6,505 | (24,227 | ) | |||||||||
| Net earnings (loss) | $ | 19,916 | $ | (831 | ) | $ | 20,040 | $ | 16,117 | ||||||
| Earnings (loss) per share | |||||||||||||||
| Basic | $ | 0.36 | $ | (0.02 | ) | $ | 0.37 | $ | 0.30 | ||||||
| Diluted | $ | 0.36 | $ | (0.02 | ) | $ | 0.36 | $ | 0.29 | ||||||
| Weighted average shares outstanding | |||||||||||||||
| Basic | 54,978,781 | 54,502,993 | 54,890,265 | 54,442,463 | |||||||||||
| Diluted | 55,724,283 | 54,502,993 | 55,675,474 | 59,035,154 | |||||||||||
| (a) Excludes amortization of intangible assets. | |||||||||||||||
| Supernus Pharmaceuticals, Inc. Reconciliations of GAAP to Non-GAAP Financial Information (Unaudited) |
Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net product sales
An itemized reconciliation between total revenues on a GAAP basis and Total revenues excluding Trokendi XR and Oxtellar XR net product sales, a non-GAAP measure, is as follows (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2024 | 2023 | Change % | 2024 | 2023 | Change % | ||||||||||||||||||
| Total revenues (GAAP)(1) | $ | 168.3 | $ | 135.5 | 24 | % | $ | 312.0 | $ | 289.3 | 8 | % | |||||||||||
| Adjustments: | |||||||||||||||||||||||
| Trokendi XR net product sales | (17.1 | ) | (19.3 | ) | (12 | )% | (33.1 | ) | (54.1 | ) | (39 | )% | |||||||||||
| Oxtellar XR net product sales | (29.5 | ) | (23.8 | ) | 24 | % | (56.5 | ) | (52.7 | ) | 7 | % | |||||||||||
| Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) | $ | 121.7 | $ | 92.4 | 32 | % | $ | 222.4 | $ | 182.5 | 22 | % | |||||||||||
| (1) Includes net product sales and royalty, licensing, and other revenues. | |||||||||||||||||||||||
Reconciliation of GAAP Operating earnings (loss) to Non-GAAP Adjusted Operating earnings
An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Operating earnings (loss) - As Reported (GAAP) | $ | 22.6 | $ | (17.6 | ) | $ | 19.4 | $ | (12.4 | ) | |||||
| Adjustments: | |||||||||||||||
| Amortization of intangible assets | 20.1 | 20.1 | 40.2 | 40.1 | |||||||||||
| Share-based compensation | 6.6 | 6.1 | 12.4 | 12.4 | |||||||||||
| Contingent consideration expense (gain) | (4.4 | ) | 0.8 | (5.5 | ) | (0.9 | ) | ||||||||
| Depreciation | 0.6 | 0.6 | 1.2 | 1.3 | |||||||||||
| Operating earnings - As Adjusted (non-GAAP) | $ | 45.5 | $ | 10.0 | $ | 67.7 | $ | 40.5 | |||||||
Non-GAAP adjusted operating earnings adjusts for non-cash items including amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, and depreciation.
Reconciliation of Full Year 2024 Financial Guidance - GAAP Operating earnings (loss) to Non-GAAP Adjusted Operating earnings
An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2024 and projected adjusted operating earnings on a non-GAAP basis for the full year 2024 is as follows (dollars in millions):
| Current Guidance (as of August 6, 2024) | Previous Guidance (as of May 8, 2024) | ||
| Operating earnings (loss) - GAAP | |||
| Adjustments: | |||
| Amortization of intangible assets | |||
| Share-based compensation | |||
| Contingent consideration expense (gain) | |||
| Depreciation | |||
| Operating earnings - As Adjusted (non-GAAP) |
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com
FAQ
What was Supernus Pharmaceuticals' (SUPN) revenue growth in Q2 2024?
How much did Qelbree sales grow for Supernus (SUPN) in Q2 2024?
What was Supernus Pharmaceuticals' (SUPN) operating income in Q2 2024?
Has Supernus (SUPN) updated its financial guidance for 2024?
